ClinicalTrials.gg
CompletedNCT05472090PREVAILUpdated Nov 26, 2024Results posted

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

A Phase 2 interventional study of TNX-102 SL and Placebo SL Tablet in Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19 and Long COVID, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 29 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-26.

Primary conditionPost-Acute COVID-19 SyndromeRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Acute COVID-19 Syndrome
Why
  1. The study's listed conditions name Post-Acute COVID-19 Syndrome, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Enrollment
67th of 155
63 · median 52
Started
2022
with 28 others
Phase 2
47 of 194
10 open now
Registered
44th of 194
by date

Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 67th largest by enrollment of the 155 interventional ones that give a count, is one of 29 that started in 2022, is one of 47 in phase 2, and was the 44th registered.

Post-Acute COVID-19 Syndrome

605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

62 of the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management of multi-site pain associated with Long COVID.

03

Conditions studied

  • Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
  • COVID-19
  • Long COVID
  • Long Haul COVID

Browse trials for

Keywords

  • Multi-site pain
  • Sleep disturbance
  • PASC
  • COVID-19
  • Long COVID
  • Coronavirus infections
04

In context

Post-Acute COVID-19 Syndrome Reclassified

605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's enrollment of 63 is close to the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.

Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • The patient is male or female, 18 to 65 years of age, inclusive.
  • The patient has a polymerase chain reaction (PCR) confirmed history of SARS-CoV-2 infection at least 3 months prior to enrollment, based on a documented written positive viral test at the time of active infection.
  • The patient has new onset or significant worsening of pain that coincides with a prior COVID-19 infection and has symptoms that have been generally present for at least 3 months but no longer than 18 months.

Major Exclusion Criteria:

  • The patient has been diagnosed with infectious or inflammatory arthritis (eg, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), systemic lupus erythematosus, untreated or active gout (ie, any acute attack within past 2 years is exclusionary), or meets criteria for another type of systemic disease (eg, Sjogren's disease).
  • The patient has been diagnosed with a complex regional pain syndrome, fibromyalgia, failed back surgery syndrome, persistent or prevalent pain symptoms related to systemic disease (eg, diabetic peripheral neuropathy, post-herpetic neuropathy), untreated hyperparathyroidism, or a history of prior surgery, trauma, organ or tissue damage, or other source of pain that, in the Investigator's opinion, would confound or interfere with the assessment of the patient's symptoms or require excluded therapies during the patient's study participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    TNX-102 SL Tablet, 5.6 mg

    1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.

    Drug: TNX-102 SL

  • Placebo comparator
    Placebo SL Tablet

    1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.

    Drug: Placebo SL Tablet

Interventions

  • Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.

  • DrugPlacebo SL Tablet

    Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.

07

What researchers measure

Primary outcomes

  1. Daily Diary Pain NRS

    Change from Baseline in the diary Numeric Rating Scale (NRS) weekly average of daily self-reported worst Long COVID pain intensity scores at the Week 14 endpoint. Scores range from 0 to 10 where a higher score means worse outcome.

    Time frame: Week 14

Secondary outcomes

  1. Daily Diary Sleep Quality NRS

    Mean change from baseline in the weekly average of the daily diary numeric rating scale (NRS) assessment of sleep quality at the Week 14 endpoint. Scores range from 0 to 10 where a higher score means worse outcome.

    Time frame: Week 14

  2. PROMIS Fatigue -Short Form 8a

    Change from Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) score for fatigue at the Week 14 endpoint. Subjects are asked to reflect on their fatigue symptoms in the past 7 days and respond to 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.

    Time frame: Week 14

  3. PROMIS Cognitive Function - Abilities-Short Form 8a

    Change from Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) score for cognitive function at the Week 14 endpoint. Subjects are asked to reflect on their cognitive function and abilities in the past 7 days and respond to 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.

    Time frame: Week 14

08

Results

Posted Nov 26, 2024
Limitations and caveats
We consider the study completed and not terminated because although participant enrollment stopped early, those that were already enrolled in the study were allowed to complete treatment and all assessments and visits per protocol. Therefore, we consider that participant's last visit has occurred.

Participant flow

Participant flow — Overall Study
MilestoneTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Started3231
Completed2625
Not completed66
Withdrew: Adverse event23
Withdrew: Lack of efficacy10
Withdrew: Physician decision10
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up03

Outcome measures

PrimaryDaily Diary Pain NRS

Change from Baseline in the diary Numeric Rating Scale (NRS) weekly average of daily self-reported worst Long COVID pain intensity scores at the Week 14 endpoint. Scores range from 0 to 10 where a higher score means worse outcome.

Time frame:
Week 14
Reported as:
Least squares mean · units on a scale
Daily Diary Pain NRS
units on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Daily Diary Pain NRS-2.2 ± 0.34-2.0 ± 0.35
SecondaryDaily Diary Sleep Quality NRS

Mean change from baseline in the weekly average of the daily diary numeric rating scale (NRS) assessment of sleep quality at the Week 14 endpoint. Scores range from 0 to 10 where a higher score means worse outcome.

Time frame:
Week 14
Reported as:
Least squares mean · units on a scale
Daily Diary Sleep Quality NRS
units on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Daily Diary Sleep Quality NRS-2.1 ± 0.38-1.6 ± 0.39
SecondaryPROMIS Fatigue -Short Form 8a

Change from Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) score for fatigue at the Week 14 endpoint. Subjects are asked to reflect on their fatigue symptoms in the past 7 days and respond to 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.

Time frame:
Week 14
Reported as:
Least squares mean · T-score
PROMIS Fatigue -Short Form 8a
T-scoreTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
PROMIS Fatigue -Short Form 8a-8.0 ± 1.65-3.2 ± 1.68
SecondaryPROMIS Cognitive Function - Abilities-Short Form 8a

Change from Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) score for cognitive function at the Week 14 endpoint. Subjects are asked to reflect on their cognitive function and abilities in the past 7 days and respond to 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.

Time frame:
Week 14
Reported as:
Least squares mean · T-score
PROMIS Cognitive Function - Abilities-Short Form 8a
T-scoreTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
PROMIS Cognitive Function - Abilities-Short Form 8a5.4 ± 1.553.5 ± 1.55

Adverse events

Collected over Patients were monitored for AEs throughout the study. The total duration of the study, including screening and follow up, was as long as 25 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNX-102 SL Tablet, 5.6 mg0/32 (0%)0/32 (0%)12/32 (37.5%)
Placebo SL Tablet0/31 (0%)0/31 (0%)2/31 (6.5%)
Most frequent other events
Most frequent other events
EventTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Hypoaesthesia oralGastrointestinal disorders6/320/31
Influenza like illnessGeneral disorders0/322/31
GlossodyniaGastrointestinal disorders2/320/31
Oral PainGastrointestinal disorders2/320/31
Paraesthesia oralGastrointestinal disorders2/320/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Mean48.6 ± 8.8051.4 ± 10.0150.0 ± 9.45
Sex: Female, Male
Sex: Female, Male(Participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Female212546
Male11617
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
American Indian or Alaska Native011
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American7512
White212445
More than one race314
Unknown or Not Reported000
BMI
BMI(kg/m^2)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Mean29.78 ± 4.06729.49 ± 4.43929.64 ± 4.222
09

Study locations

29 sites
  • Accel Research-Birmingham Clinical Research Unit
    Birmingham, Alabama 35216, United States
  • Tonix Clinical Site
    Oceanside, California 92056, United States
  • Tonix Clinical Site
    Santa Ana, California 92705, United States
  • Tonix Clinical Site
    Centennial, Colorado 80112, United States
  • Tonix Clinical Site
    Aventura, Florida 33180, United States
  • Tonix Clinical Site
    Fort Myers, Florida 33912, United States
  • Tonix Clinical Site
    Orlando, Florida 32801, United States
  • Tonix Clinical Site
    Saint Petersburg, Florida 33709, United States
  • Tonix Clinical Site
    Alpharetta, Georgia 30022, United States
  • Tonix Clinical Site
    Atlanta, Georgia 30329, United States
  • Tonix Clinical Site
    Chicago, Illinois 60625, United States
  • Tonix Clinical Site
    Des Moines, Iowa 50265, United States
  • Tonix Clinical Site
    Iowa City, Iowa 52242, United States
  • Tonix Clinical Site
    Prairie Village, Kansas 66208, United States
  • Tonix Clinical Site
    New Orleans, Louisiana 70124, United States
  • Tonix Clinical Site
    Prairieville, Louisiana 70769, United States
  • Tonix Clinical Site
    Boston, Massachusetts 02115, United States
  • Tonix Clinical Site
    Boston, Massachusetts 02131, United States
  • Tonix Clinical Site
    Methuen, Massachusetts 01844, United States
  • Tonix Clinical Site
    Gulfport, Mississippi 39503, United States
  • Tonix Clinical Site
    Albuquerque, New Mexico 87109, United States
  • Tonix Clinical Site
    New York, New York 10036, United States
  • Tonix Clinical Site
    Williamsville, New York 14221, United States
  • Tonix Clinical Site
    Shelby, North Carolina 28150, United States
  • Tonix Clinical Site
    Columbus, Ohio 43215, United States
  • Tonix Clinical Site
    Dayton, Ohio 45432, United States
  • Tonix Clinical Site
    Tulsa, Oklahoma 74133, United States
  • Tonix Clinical Site
    Austin, Texas 78737, United States
  • Tonix Clinical Site
    McKinney, Texas 75070, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jul 2023, 10 months.

Results were first posted in Nov 2024, 1 year 4 months after primary completion.

Of 63 phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2022
First posted
Jul 25, 2022
StartActual
Aug 18, 2022
Primary completionActual
Jul 12, 2023
CompletionActual
Jul 27, 2023
Results first posted
Nov 26, 2024
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05472090
Responsible party
Sponsor
First posted
Jul 25, 2022
Start date
Aug 18, 2022
Primary completion
Jul 12, 2023
Completion
Jul 27, 2023
Results posted
Nov 26, 2024
Last update
Nov 26, 2024

Study contacts

Herb Harris, MD, PhD
study director · Tonix Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion